Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC 776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Next Previous
Trial Profile

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC 776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-868

Most Recent Events

  • 06 Jun 2025 Planned End Date changed from 1 Apr 2029 to 8 May 2026.
  • 01 May 2025 Results of exploratory analysis assessing efficacy of pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer published in the Nature Medicine
  • 19 Mar 2025 According to Merck and Co media release, company announced that Health Canada approved KEYTRUDA for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top